A Study of CC-95266 in Participants With Relapsed and/or Refractory Multiple Myeloma
Clinical trial NCT04674813 · COMPLETED
Trial details
- NCT number
- NCT04674813
- Sponsor
- Juno Therapeutics, a Subsidiary of Celgene
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2021-02-24
- Primary completion
- 2025-12-22
- Enrollment
- 130
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.